Osborne Clarke provides Spin-out to Sale service to Zihipp, British obesity drug and biotech start-up

International legal practice Osborne Clarke has supported obesity and diabetes biotech start-up Zihipp on its sale to Metsera Inc., a clinical-stage biopharmaceutical company.

Led by Corporate Partner Justin Starling, who has supported Zihipp since its 2012 spin-out from Imperial College London and through its Series A funding, the Osborne Clarke team has now advised the management team and majority shareholders on the acquisition by Metsera.

Dunstan Cooke, Vice President Corporate Operations at Metsera, said:

"Osborne Clarke's team provided us with excellent advice throughout the transaction, characterised by the usual pragmatic and commercial approach we have come to expect.”

 

Osborne Clarke’s team was led by Partner Justin Starling with support from Associate Director Lesley Olsen and Associate Chris Flach. Partner Tracey Wright provided tax advice.

Osborne Clarke's international venture capital team is a go-to practice for companies operating in tech-enabled industries. From start-up through venture financing and the growth journey beyond, whether continuing to sale, IPO or international expansion, the team has an outstanding track record advising businesses, entrepreneurs and investors that are driving innovation. Osborne Clarke's dedicated resource centre, OC Ventures, brings together experts from across our international network to deliver a holistic seamless service to clients throughout the ventures ecosystem.